RNA-dependent RNA polymerase (RdRp) serves as a highly conserved, safe, and broad-spectrum antiviral target for positive-strand RNA viruses, with activity assays facilitating novel drug development.
RdRp represents a highly conserved, safe, and broad-spectrum antiviral target for the development of novel drugs against positive-strand RNA viruses.
Positive-strand RNA viruses represented by SARS-CoV-2 and DENV spread globally with high infectivity and frequent mutations, posing a severe threat to human health. However, specific and effective antiviral drugs remain limited. RNA-dependent RNA polymerase (RdRp) plays a critical role in the genome replication of RNA viruses and shows high structural conservation. No homologous protein exists in human cells, making RdRp an effective, safe, and broad-spectrum antiviral target. Therefore, establishing an RdRp activity assay for drug development based on its mechanism is of great significance. This paper summarizes the structural characteristics of RdRp and the methods for constructing RdRp activity assay, especially for cell-free activity assay. In addition, several reported RdRp inhibitors and their pharmaceutical progress are also reviewed, aiming to provide a reference for the development of novel antiviral drugs targeting RdRp.
Zhao et al. (Thu,) conducted a review in Positive-strand RNA virus infection. RdRp inhibitors was evaluated. RNA-dependent RNA polymerase (RdRp) serves as a highly conserved, safe, and broad-spectrum antiviral target for positive-strand RNA viruses, with activity assays facilitating novel drug development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: